On October 25, 2018 Provectus (OTCQB: PVCT) reported that interim results from the Company’s ongoing Phase 1b/2 study of small molecule oncolytic immunotherapy PV-10 in combination with KEYTRUDA (pembrolizumab), an anti-PD-1 immune checkpoint inhibitor, were presented at the 15th International Congress of the Society for Melanoma Research (SMR 2018 Congress), held in Manchester, England from October 24-27, 2018 (Press release, Provectus Biopharmaceuticals, OCT 25, 2018, View Source [SID1234530152]). Intratumoral injection of PV-10 can yield immunogenic cell death in solid tumor cancers and stimulate tumor-specific reactivity in circulating T cells.1-4
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Phase 1b portion of the study completed enrollment in April 2018 of 23 patients with metastatic melanoma at clinical sites in the U.S. (NCT02557321). Patients with at least one injectable lesion and who were candidates for KEYTRUDA were eligible. Eligible subjects received the combination treatment of PV-10 and KEYTRUDA every three weeks for up to five cycles (i.e., over a period of up to 12 weeks, with no further PV-10 administered after week 12), followed by only KEYTRUDA every three weeks for up to 24 months. The primary endpoint for the Phase 1b trial was safety and tolerability. Objective response rate and progression-free survival were key secondary endpoints (both assessed via RECIST 1.1 after five treatment cycles, and then every 12 weeks thereafter). Response follow-up of 6 patients (26%) is ongoing.
Interim Results from the Presentation at SMR:
Baseline characteristics: 83% men; median age of 70 years (range 28-90) and 70% > 65 years; 91% checkpoint naïve.
Disease characteristics: 13% Stage IIIC/IIID and 52% Stage IV M1b/M1c; median of 2 cutaneous/subcutaneous lesions (range 1-15)5; most subjects had substantial non-injected systemic disease burden in addition to their injectable cutaneous and/or subcutaneous lesions.
Treatment summary: Subjects received a median of 4 cycles of PV-10 (mean 3.7, range 1-5) and a median of 5 injections of PV-10 (range 1-82); PV-10 was not administered after week 12.
Preliminary safety: adverse events were consistent with the established patterns for single-agent use of each drug; there were no unexpected toxicities or evidence of significant overlapping toxicity.
Preliminary target lesion efficacy (best overall response): 43% complete response and 65% objective response.
Preliminary overall efficacy (per RECIST 1.1): 9% complete response, 65% objective response, and 70% clinical benefit; 83% objective response in M1c patients.
The Company currently plans to present durability and survival data from these study participants at a medical conference in the first half of 2019. Provectus plans to open an expansion cohort of up to 24 patients in the Phase 1b portion of the study to assess the PV-10-KEYTRUDA combination in patients who have failed to respond to initial treatment with checkpoint inhibition.
Dominic Rodrigues, Vice Chair of the Company’s Board of Directors, said, "These updated results continue to highlight the non-overlapping safety profiles of PV-10 and checkpoint inhibition by authenticating the lack of correlation of adverse events between the two drugs. The data also continue to demonstrate the promising clinical benefit of cancer combination therapy with checkpoint inhibition after minimal PV-10 intervention.6 We believe successful combination therapy is achieved by pairing drugs that each show single-agent activity."
A copy of the poster presentation is currently available on Provectus’ website at
View Source
About PV-10
Provectus’ lead investigational oncology drug, PV-10, the first small molecule oncolytic immunotherapy, can induce immunogenic cell death. PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and cancers of the liver, and preclinical study for pediatric cancers.